Latest News

New genomic insights reveal how pirtobrutinib effectively targets resistance in relapsed CLL, reshaping treatment strategies for better outcomes.

New research reveals that combining midostaurin with standard chemotherapy significantly improves survival rates and reduces minimal residual disease in AML patients.

Patients with Waldenström macroglobulinemia experience comparable outcomes when switching from ibrutinib to zanubrutinib, with improved safety profiles.

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

During a live event, Matthew Lunning, DO, interpreted long-term outcomes of the ZUMA-7 and TRANSFORM trials.

A phase 2 trial shows ribociclib and letrozole effectively treat recurrent low-grade serous carcinoma, achieving significant response rates and durable control.

A groundbreaking study reveals that ultrasensitive ctDNA assays significantly enhance prognosis for large B-cell lymphoma, outperforming traditional PET assessments.

Research uncovers distinct sex-based differences in exosomal ncRNA dysregulation in multiple myeloma, highlighting the need for personalized treatment strategies.

A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent high-grade bladder cancer, emphasizing patient-centered care.

Dena Champion leads a transformative initiative for cancer survivors, blending nutrition, community, and gardening to promote health and well-being.

Key FDA action dates in early 2026 promise to transform treatment options for solid tumors and rare hematologic malignancies, enhancing patient care.

Digital pathology revolutionizes diagnostics with AI and imaging, enhancing accuracy, speed, and personalized medicine for improved patient care.

Discover groundbreaking advancements in glioblastoma treatment, including FDA approvals and innovative therapies reshaping neuro-oncology in 2025.

Explore groundbreaking FDA approvals in oncology for 2025, enhancing treatment options for breast cancer, lung cancer, and rare tumors.

Discover the latest breakthroughs in multiple myeloma treatment, including CAR T-cell therapies and promising new options for relapsed patients.

December 2025 marks a transformative month in oncology, showcasing groundbreaking FDA approvals and designations that enhance cancer treatment options.

Melanoma treatment advances with lifileucel's promising efficacy, regulatory updates, and innovative therapies, shaping a hopeful landscape for patients.

A groundbreaking bladder cancer treatment, TAR-200, offers new hope for patients failing first-line therapy, showcasing impressive response rates and ease of use.

Breakthroughs in GI cancer treatment in 2025 showcase innovative therapies, including daraxonrasib for pancreatic cancer and aspirin's role in colorectal cancer recurrence.

2025 marks a transformative year in thoracic oncology, showcasing groundbreaking FDA approvals for targeted therapies in lung cancer treatment.

Hematologic oncology sees breakthroughs in treatment efficacy and regulatory challenges, highlighting advancements in BTK degraders and essential thrombocythemia therapies.

Discover groundbreaking advancements in urologic oncology, including new standards for prostate, kidney, and bladder cancer treatments that enhance patient outcomes.

Discover groundbreaking advancements in gynecologic oncology, offering new hope for patients with challenging cancers through innovative therapies and clinical trials.

Breakthroughs in breast cancer treatment in 2025 highlight FDA approvals and innovative therapies, enhancing outcomes for HR+, HER2–, and TNBC patients.

A new study reveals that common chronic medications do not impact the effectiveness of immune checkpoint inhibitors in metastatic lung cancer treatment.

A new study reveals FOLFIRINOX chemotherapy is feasible for select elderly patients with pancreatic cancer, highlighting safety and survival outcomes.

During a live event, Kathryn E. Beckermann, MD, PhD, and participants discussed whether risk stratification factors into the choice of a combination regimen for advanced renal cell carcinoma.

New study reveals a blood-based test effectively detects cancers in survivors, bridging the surveillance gap and enhancing long-term monitoring.

AstraZeneca and Daiichi Sankyo launch a pivotal trial to assess T-DXd as a potential adjuvant therapy for HER2-expressing endometrial cancer.

FDA approves mosunetuzumab-axgb for quick subcutaneous treatment of relapsed follicular lymphoma, enhancing patient care and reducing clinic time.

Pirtobrutinib shows significant efficacy and safety in treating relapsed/refractory follicular lymphoma, with promising response rates and durable outcomes.